30 results on '"Soto Parra, Hector J."'
Search Results
2. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
3. Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
4. Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.
5. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.
6. Gemcitabine and Vinorelbine in Pemetrexed-Pretreated Patients With Malignant Pleural Mesothelioma
7. Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study.
8. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
9. Multicenter study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).
10. Excision repair cross complementation group 1 (ERCC-1) gene polymorphisms and response to nivolumab in advanced non-small cell lung cancer (NSCLC).
11. A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
12. Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
13. Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.
14. Efficacy of mitomycin C plus a fluoropyrimidine in pretreated patients with metastatic colorectal cancer eligible to regorafenib: Results of a retrospective study.
15. Multi-istitutional study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).
16. Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.
17. The role of cisplatin (CDDP) or carboplatin (CARBO) plus pemetrexed (PEM) in nonsquamous (NON-SQM) non-small cell lung cancer (NSCLC): Results of an Italian retrospective multicentric study.
18. Role of trastuzumab in infracentimetric HER2-positive breast cancer: The southern Italy experience.
19. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
20. Retrast: Retreatment after adjuvant trastuzumab—Our regional southern Italy experience.
21. Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib.
22. P1-092: Predictive value of fluorodeoxyglucose uptake by positron emission tomography and in refractory non-small-cell lung cancer treated with erlotinib: preliminary results
23. P-619 Analysis of responses to gefitinib (ZD 1839 IressaTM) according to epidermal growth factor receptor (EGFR) expressed as staining intensity or percentage of immunoreactive cells
24. P-4 Preliminary results of an intensified 3-day schedule of cisplatin (P) and vinorelbine (V) as induction treatment in prognostically unfavorable locally advanced non-small-cell lung cancer (LA-NSCLC)
25. P-32 Feasibility of combination of cisplatin (C) and gemcitabine (G) in non-small cell lung cancer (NSCLC): Analysis of dose-intensity (DI) and compliance of four different schedules
26. P-618 ZD 1839 (Iressa) in elderly patients with progressive pretreated non small cell lung cancer (NSCLC): Results at the Istituto clinico humanitas, Rozzano, Milano
27. P-519 Proposals of combined approaches to thymoma: A monocentric experience
28. EVALUATION OF ERLOTINIB TREATMENT RESPONSE IN NON-SMALL CELL LUNG CANCER USING EORTC METABOLIC CRITERIA, PERCIST AND ANATOMIC CRITERIA RECIST
29. Predictive value of fluorodeoxyglucose uptake by positron emission tomography and in refractory non-small-cell lung cancer treated with erlotinib: preliminary results.
30. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.